| Cell line name |
BON1 RR1 |
|---|
| Synonyms |
RR1 |
|---|
| Accession |
CVCL_WV97 |
|---|
| Resource Identification Initiative |
To cite this cell line use: BON1 RR1 (RRID:CVCL_WV97) |
|---|
| Comments |
Selected for resistance to: ChEBI; CHEBI_68478; Everolimus (RAD001).
Derived from site: Metastatic; Lymph node; UBERON=UBERON_0000029. |
|---|
| Sequence variations |
- Gene deletion; HGNC; HGNC:1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
- Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:583; APC; Simple; p.Glu1317Gln (c.3949G>C); ClinVar=VCV000000829; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:1101; BRCA2; Simple; p.Cys1960Tyr (c.5879G>A); ClinVar=VCV000038003; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; HGNC:11998; TP53; Simple; p.Arg342Ter (c.1024C>T); ClinVar=VCV000182970; Zygosity=Homozygous (from parent cell line).
|
|---|
| Disease |
Pancreatic serotonin-producing neuroendocrine tumor (NCIt: C4446)
Serotonin-producing neuroendocrine tumor of pancreas (ORDO: Orphanet_506090) |
|---|
| Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
|---|
| Hierarchy |
Parent: CVCL_3985 (BON-1) |
|---|
| Sex of cell |
Male |
|---|
| Age at sampling |
28Y |
|---|
| Category |
Cancer cell line |
|---|
| Publications | DOI=10.1530/endoabs.49.EP154
Elke Tatjana Aristizabal Prada, Julian Maurer, Gerald Spottl, Christoph Joseph Auernhammer, Svenja Nolting;
Development of an everolimus-resistant BON1 cell line with altered cell cycle and c-Met activity.
Endocr. Abstr. 49:EP154-EP154(2017) PubMed=29895527; DOI=10.1530/ERC-18-0159; PMCID=PMC7439002
Elke Tatjana Aristizabal Prada, Gerald Spottl, Julian Maurer, Michael Lauseker, Eva Jolanthe Koziolek, Jorg Schrader, Ashley Grossman, Karel Pacak, Felix Beuschlein, Christoph Joseph Auernhammer, Svenja Nolting;
The role of GSK3 and its reversal with GSK3 antagonism in everolimus resistance.
Endocr. Relat. Cancer 25:893-908(2018) |
|---|
| Cross-references |
|---|
| Cell line databases/resources |
cancercelllines; CVCL_WV97
|
|---|
| Encyclopedic resources |
Wikidata; Q93430380
|
|---|
| Entry history |
|---|
| Entry creation | 06-Sep-2019 |
|---|
| Last entry update | 19-Dec-2024 |
|---|
| Version number | 10 |
|---|
